Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed/Refractory, High Risk Hematologic Malignancies”

284 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 284 results

Early research (Phase 1)Study completedNCT01149915
What this trial is testing

Study of Hypoxia-Activated Prodrug TH-302 to Treat Advanced Leukemias

Who this might be right for
Acute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaChronic Myelogenous Leukemia+3 more
Threshold Pharmaceuticals 40
Early research (Phase 1)Active Not RecruitingNCT05878184
What this trial is testing

Study Evaluating SC291 in Subjects With r/r B-cell Malignancies (ARDENT)

Who this might be right for
Non Hodgkin LymphomaChronic Lymphocytic Leukemia
Sana Biotechnology 16
Testing effectiveness (Phase 2)WithdrawnNCT04044209
What this trial is testing

The IDH1 Inhibitor AG-120 in Combination With the Checkpoint Blockade Inhibitor, Nivolumab, for Patients With IDH1 Mutated Relapsed/Refractory AML and High Risk MDS

Who this might be right for
Myelodysplastic SyndromesAcute Myeloid Leukemia
Yale University
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07562568
What this trial is testing

SHR2554/AZA + Overlapped TBF for High-risk/Relapsed Leukemia/MDS

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMDS+4 more
The First Affiliated Hospital of Soochow University 160
Testing effectiveness (Phase 2)Study completedNCT00475150
What this trial is testing

Cediranib Maleate in Treating Patients With Relapsed, Refractory, or Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Adult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)+8 more
National Cancer Institute (NCI) 39
Testing effectiveness (Phase 2)Study completedNCT02044796
What this trial is testing

Filgrastim, Cladribine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With Newly Diagnosed or Relapsed/Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

Who this might be right for
Acute Biphenotypic Leukemiade Novo Myelodysplastic SyndromePreviously Treated Myelodysplastic Syndrome+3 more
Fred Hutchinson Cancer Center 199
Testing effectiveness (Phase 2)Study completedNCT00047021
What this trial is testing

Combination Chemotherapy in Treating Patients With Recurrent or Refractory Leukemia or Lymphoma

Who this might be right for
LeukemiaLymphoma
Case Comprehensive Cancer Center 3
Early research (Phase 1)Study completedNCT00058292
What this trial is testing

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Northwestern University 44
Not applicableLooking for participantsNCT05237258
What this trial is testing

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Who this might be right for
Relapsed Adult AMLPrimary Refractory Acute Myeloid LeukemiaHigh Risk Acute Myeloid Leukemia
Massachusetts General Hospital 2,300
Testing effectiveness (Phase 2)Ended earlyNCT02152956
What this trial is testing

Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)

Who this might be right for
AML
MacroGenics 244
Early research (Phase 1)Looking for participantsNCT07225439
What this trial is testing

Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

Who this might be right for
Non Hodgkin LymphomaB-cell Non Hodgkin LymphomaDiffuse Large B Cell Lymphoma+7 more
Paolo Caimi, MD 15
Very early researchUnknownNCT03795779
What this trial is testing

CLL1-CD33 cCAR in Patients With Relapsed and/or Refractory, High Risk Hematologic Malignancies

Who this might be right for
Hematologic MalignancyAcute Myeloid LeukemiaMyelodysplastic Syndromes+2 more
iCell Gene Therapeutics 20
Early research (Phase 1)Study completedNCT02332850
What this trial is testing

Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Thomas Martin, MD 83
Testing effectiveness (Phase 2)Study completedNCT02481297
What this trial is testing

Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Who this might be right for
LeukemiaChronic Lymphocytic LeukemiaLymphocytic Leukemia
M.D. Anderson Cancer Center 7
Large-scale testing (Phase 3)Study completedNCT00005863
What this trial is testing

Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia

Who this might be right for
LeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Neoplasms
Medical Research Council
Testing effectiveness (Phase 2)Looking for participantsNCT04047641
What this trial is testing

Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

Who this might be right for
Acute Myeloid LeukemiaBlasts 20 Percent or More of Bone Marrow Nucleated CellsHigh Risk Myelodysplastic Syndrome+5 more
M.D. Anderson Cancer Center 80
Not applicableStudy completedNCT03389347
What this trial is testing

High Throughput Drug Sensitivity and Genomics Data in Developing Individualized Treatment in Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

Who this might be right for
Plasma Cell LeukemiaRecurrent Multiple MyelomaRefractory Multiple Myeloma
University of Washington 40
Testing effectiveness (Phase 2)Study completedNCT02768792
What this trial is testing

High Dose Cytarabine Followed by Pembrolizumab in Relapsed/Refractory AML

Who this might be right for
Acute Myeloid Leukemia, in Relapse
UNC Lineberger Comprehensive Cancer Center 38
Large-scale testing (Phase 3)Study completedNCT01311687
What this trial is testing

A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

Who this might be right for
Multiple Myeloma
Celgene 455
Testing effectiveness (Phase 2)Active Not RecruitingNCT04623541
What this trial is testing

Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter's Syndrome

Who this might be right for
Relapsed/Refractory Chronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaRichter's Syndrome+1 more
Genmab 194
Next Page